Results 111 to 120 of about 8,266,387 (310)

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Molecular Cancer
Background The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge.
Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E. Raez, Christian Rolfo, Daniel Ajona, Ignacio Gil-Bazo   +16 more
doaj   +1 more source

Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells

Journal for ImmunoTherapy of Cancer
Background Epithelial to mesenchymal transition (EMT) endows cancer cells with pro-metastatic properties, which appear most effective when cells enter an intermediate hybrid (H) state, characterized by integrated mesenchymal (M) and epithelial (E) traits.
Ugo Pastorino, Massimo Milione, Paola Orecchia, Massimo Moro, Gabriella Sozzi, Monica Parodi, Giovanni Centonze, Fabio Murianni, Francesca Andriani, Ilaria Roato, Cecilia Gardelli, Melissa Balsamo, Giulia Taiè, Andrea Petretto, Chiara Lavarello ‎, Luca Roz, Massimo Vitale, Giulia Bertolini   +17 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy

, 2019
Esteban Cruz, Veysel KayserSchool of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaAbstract: Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of a wide range of solid tumors.
Kayser V, Cruz E
core  

Portal vein thrombosis and arterioportal shunts : effects on tumor response after chemoembolization of hepatocellular carcinoma [PDF]

, 2011
AIM: To evaluate the effect of portal vein thrombosis and arterioportal shunts on local tumor response in advanced cases of unresectable hepatocellular carcinoma treated by transarterial chemoembolization.
Ackermann, Hans, Mohammed, Nour-Eldin Abdelrehim Nour-Eldin, Trojan, Jörg, Emad-Eldin, Sally, Abdelaziz, Omar, Naguib, Nagy Naguib Naeem, Vogl, Thomas J.   +6 more
core   +1 more source

Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors

, 2022
INTRODUCTION: The relationship between cancers and thromboembolic events is well established. In our study, we aim to determine the burden of thromboembolic events in patients with solid tumors and identify the risk factors related to their development ...
Alkhaldi, Turkiah, Aseafan, Mohamed, Aljumaa, Jihad, Alghabban, Abdulrahman, Almuhisen, Sara, Owaidah, Tarek, Alzahrani, Hazzaa, Eldali, Abdelmoneim, Melaibari, Maryam, Maraiki, Fatma, Bazarbashi, Shouki, Alharbi, Samar   +11 more
core   +1 more source

Retrospective Cohort Study of Intrapericardial Cisplatin for Risk Reduction of Malignant Pericardial Effusion Recurrence

Current Oncology
Malignant pericardial effusion (MPE) is a life-threatening condition in patients with cancer, with common recurrences after simple pericardiocentesis.
Francisco Javier Muñoz-Carrillo, Roxana Maribel Reyes, David Pesántez, Gemma Carrera, Enric Cascos, Pedro Castro, Sara Fernández-Méndez, Carme Font, Laura González-Aguado, Ignacio Grafiá, Lucía Llavata, Inés Monge-Escartín, Joan Padrosa, Noemí Reguart, Adrián Téllez, Albert Tuca, Margarita Viladot, Carles Zamora-Martínez, Patrícia Amorós-Reboredo, Javier Marco-Hernández   +19 more
doaj   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Monoclonal antibodies and Fc fragments for treating solid tumors

, 2012
Andrea M Eisenbeis, Stefan J GrauDepartment of Neurosurgery, University Hospital of Cologne, Cologne, GermanyAbstract: Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number ...
Eisenbeis AM, Grau SJ
core  

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source